Salta al contingut

Hair Loss with Ozempic or Mounjaro: Causes and Solutions

Hair loss can be a side effect of GLP-1 medication (Ozempic, Mounjaro) due to rapid weight loss. At Santé Clínica Estética, we address this issue with a medical and personalized approach.

September 27, 2026
thumbnail.png

Why can GLP-1 medication (Ozempic, Mounjaro) cause hair loss?

GLP-1 medication, such as Ozempic or Mounjaro, used for weight management, can cause temporary hair loss in some patients. This is primarily due to the rapid and significant weight reduction that these drugs induce. The body interprets this accelerated weight loss as physiological stress, which can trigger a condition known as telogen effluvium.

Telogen effluvium is an alteration of the hair growth cycle. Normally, hair goes through phases of growth (anagen), transition (catagen), and rest (telogen). During a period of stress, a greater number of hair follicles prematurely enter the resting phase and subsequently fall out after two or three months. This shedding is usually diffuse and reversible once the body adapts to the changes.

It is important to note that GLP-1 medication itself is not usually the direct cause of the shedding. Rather, it is the body's response to rapid weight loss and associated metabolic changes. Medical literature suggests that rapid weight loss, regardless of the method, can induce this type of telogen effluvium. For example, a study published in the Journal of the American Academy of Dermatology (2017) on weight loss and post-bariatric telogen effluvium, although not directly about GLP-1, illustrates how metabolic stress can trigger this condition.

The hair cycle and telogen effluvium

To better understand telogen effluvium, it is helpful to visualize the hair life cycle:

Hair cycle flowchart: Anagen, Catagen, Telogen, and Exogen.
  1. Anagen Phase: Active Growth (2-7 years
  2. Catagen Phase: Transition (2-3 weeks
  3. Telogen Phase: Rest (2-3 months
  4. Exogen Phase: Shedding and New Growth

In telogen effluvium, a higher than normal proportion of follicles prematurely transition from the anagen to the telogen phase, resulting in diffuse hair shedding a few months after the stressful event.

Key points

  • Telogen effluvium: The most common cause of hair loss associated with GLP-1 medication is telogen effluvium, triggered by the stress of rapid weight loss.
  • Temporary nature: Generally, this condition is temporary, and hair tends to recover once the body adapts to weight changes.
  • Medical approach: It is essential to consult a doctor to assess the situation and determine the best course of action.
  • Supportive treatments: There are medical treatments that can strengthen hair and stimulate its growth during this period.

How Santé Clínica Estética addresses it

At Santé Clínica Estética, we understand the concern caused by hair loss. Our medical team addresses this situation with a personalized protocol and under professional supervision. The first step is a detailed medical evaluation to understand your history and the specific causes of the shedding.

We offer a free hair consultation where our specialists will assess your case. We speak Spanish, English, Portuguese, and Russian to ensure fluid communication. Our goal is to establish a treatment protocol that not only stops hair loss but also promotes hair regeneration.

Our treatments focus on nourishing and stimulating the hair follicle. They include options such as:

  • Hair mesotherapy: Microinjections of vitamins, minerals, and amino acids are administered directly into the scalp to nourish the follicles.
  • PRP (Platelet-Rich Plasma): Uses growth factors from your own blood to stimulate cell regeneration and hair growth.
  • Hair exosomes: Advanced treatment that uses extracellular vesicles to communicate and repair cells, promoting an optimal environment for hair growth.
  • Intensive protocols: Combination of exosomes with specific anti-hair-loss treatments to support hair health.

Results may vary depending on the individual and adherence to the protocol. Hair recovery is a gradual process that requires patience and medical follow-up.

Hair recovery timeline (illustrative example)

Hair recovery after telogen effluvium induced by weight loss is a gradual process. Below is an illustrative timeline, although individual results may vary significantly:

Period What to expect (without specific treatment) Possible effects with medical treatment at Santé
0-3 months (from onset of shedding) More noticeable hair shedding. Medical evaluation, initiation of mesotherapy/PRP. Possible support in reducing shedding.
3-6 months Shedding may begin to decrease. Onset of new, fine hair growth. Continuation of treatments. Possible support for new hair growth.
6-12 months Gradual recovery of hair density and thickness. Possible support for hair density and quality. Maintenance as needed.
12+ months Full recovery in most cases. Possible support for healthier, stronger hair.

Frequently asked questions

Is hair loss permanent?

No, hair loss associated with GLP-1 medication and rapid weight loss is usually temporary. It is classified as telogen effluvium, a reversible condition where hair follicles recover and hair regrows, although the process can take several months.

Should I stop taking my GLP-1 medication if I lose hair?

You should not stop your medication without first consulting your prescribing doctor. It is crucial to discuss any side effects with them. At Santé Clínica Estética, we can offer you a hair support plan that complements your main treatment, always in communication with your doctor.

What treatments does Santé offer for hair loss?

At Santé, we offer hair mesotherapy, PRP (Platelet-Rich Plasma) treatments, and hair exosomes. These treatments are designed to nourish the follicle, stimulate growth, and strengthen existing hair. Each plan is personalized after a medical evaluation.

When can the effects of hair treatments be observed?

The effects of hair treatments are gradual. Generally, an improvement in hair condition and a possible reduction in shedding can be observed over time, but individual results vary. Consistency and medical follow-up are key to supporting results.

Generalitat de Catalunya - Departament de Salut - Direcció General d'Ordenació i Regulació SanitàriaFinanciado por la Unión Europea - NextGenerationEU, Gobierno de España, ENISA, Plan de Recuperación, Transformación y Resiliencia